Vericel Secures $197M Contract with U.S. BARDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VCEL?
Source: seekingalpha
- Significant Contract Value: Vericel has secured a 10-year contract worth up to $197 million with U.S. BARDA, including a $35 million base contract that allocates approximately $10 million for initial supply and early development over the next 12 months, indicating strong growth potential in the medical sector.
- Strategic Stockpile Expansion: Effective April 1, 2026, the contract allows for optional additional orders to expand the Strategic National Stockpile, highlighting Vericel's critical role in addressing public health emergencies and further solidifying its market position.
- Product Application Outlook: The early development focus on blast trauma applications is expected to drive demand for NexoBrid, enhancing the company's competitive edge in trauma treatment and laying the groundwork for future revenue growth.
- Revenue Forecast Increase: Vericel targets revenue between $316 million and $326 million in 2026, driven by the expansion of its MACI sales force and accelerating MACI arthro adoption, reflecting a proactive strategy in new product promotion and market penetration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VCEL
Wall Street analysts forecast VCEL stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 32.560
Low
55.00
Averages
57.67
High
60.00
Current: 32.560
Low
55.00
Averages
57.67
High
60.00
About VCEL
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vericel Secures $197 Million BARDA Contract
- Significant Contract Value: Vericel Corporation has secured a ten-year contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $197 million, with a base contract amount of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months.
- Strategic Importance: This contract encompasses not only the procurement of NexoBrid but also the establishment and maintenance of a Vendor Managed Inventory (VMI) system and the design and validation of a U.S. manufacturing facility, highlighting Vericel's critical role in addressing major public health emergencies.
- Market Expansion Potential: The contract includes options for additional NexoBrid procurement to expand the Strategic National Stockpile and funding for further clinical development for a potential blast trauma indication, indicating significant growth potential for the company in the market.
- Leadership Confidence: Vericel's CEO Nick Colangelo stated that this partnership will support U.S. national preparedness for severe burns and blast trauma injuries, further solidifying the clinical value and utilization of NexoBrid in the U.S. market.
See More
Vericel Secures $197M Contract with U.S. BARDA
- Significant Contract Value: Vericel has secured a 10-year contract worth up to $197 million with U.S. BARDA, including a $35 million base contract that allocates approximately $10 million for initial supply and early development over the next 12 months, indicating strong growth potential in the medical sector.
- Strategic Stockpile Expansion: Effective April 1, 2026, the contract allows for optional additional orders to expand the Strategic National Stockpile, highlighting Vericel's critical role in addressing public health emergencies and further solidifying its market position.
- Product Application Outlook: The early development focus on blast trauma applications is expected to drive demand for NexoBrid, enhancing the company's competitive edge in trauma treatment and laying the groundwork for future revenue growth.
- Revenue Forecast Increase: Vericel targets revenue between $316 million and $326 million in 2026, driven by the expansion of its MACI sales force and accelerating MACI arthro adoption, reflecting a proactive strategy in new product promotion and market penetration.
See More
MediWound Reports $197 Million BARDA Contract Award to Vericel for NexoBrid
- Significant Contract Value: Vericel has been awarded a ten-year contract by BARDA valued at up to $197 million, with a base contract of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months, indicating strong demand and market potential for the product.
- Strategic Inventory Management: The contract includes the establishment and maintenance of a Vendor Managed Inventory (VMI) system, which will optimize the supply chain management of NexoBrid, ensuring rapid response in emergencies and enhancing the company's competitiveness in the medical emergency sector.
- Manufacturing Capacity Enhancement: The contract also involves plans for the design and validation of a U.S.-based manufacturing facility, which will not only reduce production costs but also enhance Vericel's production capabilities in the U.S. market, further driving NexoBrid's market penetration.
- New Formulation Development: Vericel will develop a next-generation formulation of NexoBrid and explore additional indications for blast trauma treatment, which is expected to broaden the product's applicability and strengthen the company's strategic position in the biopharmaceutical market.
See More
Vericel Receives Approval for MACI Commercial Production
- Regulatory Milestone: Vericel Corporation has received FDA approval to commence commercial manufacturing of MACI® at its state-of-the-art facility in Burlington, Massachusetts, marking a significant achievement in complex cell therapy manufacturing, with production expected to start in Q2 2026.
- Capacity Expansion: This approval enables Vericel to increase production capacity for its restorative cartilage repair product to meet rising market demand, further solidifying its leadership position in the sports medicine and severe burn care markets.
- Supply Chain Enhancement: The new facility's operational launch will strengthen the company's supply chain capabilities, supporting its mission to deliver innovative, high-quality therapies to patients while laying a foundation for long-term value creation for shareholders.
- International Market Potential: With the commercialization of MACI, Vericel plans to expand its reach into markets outside the U.S., further broadening its global business and seizing growth opportunities in international markets.
See More
Vericel Corporation to Present at Upcoming Investor Conferences
- Investor Conference Schedule: Vericel Corporation will present at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, and at the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026, showcasing its advanced therapies in sports medicine and severe burn care.
- Webcast Availability: The company will provide a webcast of the presentations on its Investor Relations section of the website, ensuring that investors can access real-time updates, thereby enhancing transparency and investor confidence.
- Product Portfolio Strength: Vericel markets three key products in the U.S., including MACI® and Epicel®, which combine innovations in biology with medical technologies aimed at repairing injuries and improving patient quality of life, demonstrating the company's competitiveness in the industry.
- Market Positioning: As a leader in the sports medicine and severe burn care markets, Vericel is committed to meeting patient needs and driving long-term growth through its unique cell therapies and specialty biologics, further solidifying its market position.
See More
Vericel Corporation Reports Strong Q4 2025 Earnings with Record Revenue Growth
- Record Financial Performance: Vericel Corporation reported fourth quarter total revenue of $92.9 million, reflecting a 23% year-over-year growth, with full-year revenue reaching $276.3 million, exceeding expectations and showcasing the company's strong market performance and profitability.
- Significant MACI Sales Growth: The MACI product line generated over $84.1 million in revenue during Q4, marking a 23% increase compared to the previous year and a 51% sequential growth, indicating substantial progress in expanding market share and product acceptance.
- Strategic Investments and Expansion: The company plans to continue expanding its MACI sales force in 2026 while advancing the MACI Ankle clinical study and international market expansion, with projected MACI revenue guidance of $280 million to $286 million for the full year, reflecting confidence in future growth.
- Cash Flow and Financial Health: By the end of 2025, the company reported approximately $200 million in cash and investments with no debt, alongside an operating cash flow of $52 million for the year, demonstrating robust financial management and operational efficiency.
See More
Vericel Secures $197 Million BARDA Contract
- Significant Contract Value: Vericel Corporation has secured a ten-year contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $197 million, with a base contract amount of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months.
- Strategic Importance: This contract encompasses not only the procurement of NexoBrid but also the establishment and maintenance of a Vendor Managed Inventory (VMI) system and the design and validation of a U.S. manufacturing facility, highlighting Vericel's critical role in addressing major public health emergencies.
- Market Expansion Potential: The contract includes options for additional NexoBrid procurement to expand the Strategic National Stockpile and funding for further clinical development for a potential blast trauma indication, indicating significant growth potential for the company in the market.
- Leadership Confidence: Vericel's CEO Nick Colangelo stated that this partnership will support U.S. national preparedness for severe burns and blast trauma injuries, further solidifying the clinical value and utilization of NexoBrid in the U.S. market.
See More
Vericel Secures $197M Contract with U.S. BARDA
- Significant Contract Value: Vericel has secured a 10-year contract worth up to $197 million with U.S. BARDA, including a $35 million base contract that allocates approximately $10 million for initial supply and early development over the next 12 months, indicating strong growth potential in the medical sector.
- Strategic Stockpile Expansion: Effective April 1, 2026, the contract allows for optional additional orders to expand the Strategic National Stockpile, highlighting Vericel's critical role in addressing public health emergencies and further solidifying its market position.
- Product Application Outlook: The early development focus on blast trauma applications is expected to drive demand for NexoBrid, enhancing the company's competitive edge in trauma treatment and laying the groundwork for future revenue growth.
- Revenue Forecast Increase: Vericel targets revenue between $316 million and $326 million in 2026, driven by the expansion of its MACI sales force and accelerating MACI arthro adoption, reflecting a proactive strategy in new product promotion and market penetration.
See More
MediWound Reports $197 Million BARDA Contract Award to Vericel for NexoBrid
- Significant Contract Value: Vericel has been awarded a ten-year contract by BARDA valued at up to $197 million, with a base contract of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months, indicating strong demand and market potential for the product.
- Strategic Inventory Management: The contract includes the establishment and maintenance of a Vendor Managed Inventory (VMI) system, which will optimize the supply chain management of NexoBrid, ensuring rapid response in emergencies and enhancing the company's competitiveness in the medical emergency sector.
- Manufacturing Capacity Enhancement: The contract also involves plans for the design and validation of a U.S.-based manufacturing facility, which will not only reduce production costs but also enhance Vericel's production capabilities in the U.S. market, further driving NexoBrid's market penetration.
- New Formulation Development: Vericel will develop a next-generation formulation of NexoBrid and explore additional indications for blast trauma treatment, which is expected to broaden the product's applicability and strengthen the company's strategic position in the biopharmaceutical market.
See More
Vericel Receives Approval for MACI Commercial Production
- Regulatory Milestone: Vericel Corporation has received FDA approval to commence commercial manufacturing of MACI® at its state-of-the-art facility in Burlington, Massachusetts, marking a significant achievement in complex cell therapy manufacturing, with production expected to start in Q2 2026.
- Capacity Expansion: This approval enables Vericel to increase production capacity for its restorative cartilage repair product to meet rising market demand, further solidifying its leadership position in the sports medicine and severe burn care markets.
- Supply Chain Enhancement: The new facility's operational launch will strengthen the company's supply chain capabilities, supporting its mission to deliver innovative, high-quality therapies to patients while laying a foundation for long-term value creation for shareholders.
- International Market Potential: With the commercialization of MACI, Vericel plans to expand its reach into markets outside the U.S., further broadening its global business and seizing growth opportunities in international markets.
See More
Vericel Corporation to Present at Upcoming Investor Conferences
- Investor Conference Schedule: Vericel Corporation will present at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, and at the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026, showcasing its advanced therapies in sports medicine and severe burn care.
- Webcast Availability: The company will provide a webcast of the presentations on its Investor Relations section of the website, ensuring that investors can access real-time updates, thereby enhancing transparency and investor confidence.
- Product Portfolio Strength: Vericel markets three key products in the U.S., including MACI® and Epicel®, which combine innovations in biology with medical technologies aimed at repairing injuries and improving patient quality of life, demonstrating the company's competitiveness in the industry.
- Market Positioning: As a leader in the sports medicine and severe burn care markets, Vericel is committed to meeting patient needs and driving long-term growth through its unique cell therapies and specialty biologics, further solidifying its market position.
See More
Vericel Corporation Reports Strong Q4 2025 Earnings with Record Revenue Growth
- Record Financial Performance: Vericel Corporation reported fourth quarter total revenue of $92.9 million, reflecting a 23% year-over-year growth, with full-year revenue reaching $276.3 million, exceeding expectations and showcasing the company's strong market performance and profitability.
- Significant MACI Sales Growth: The MACI product line generated over $84.1 million in revenue during Q4, marking a 23% increase compared to the previous year and a 51% sequential growth, indicating substantial progress in expanding market share and product acceptance.
- Strategic Investments and Expansion: The company plans to continue expanding its MACI sales force in 2026 while advancing the MACI Ankle clinical study and international market expansion, with projected MACI revenue guidance of $280 million to $286 million for the full year, reflecting confidence in future growth.
- Cash Flow and Financial Health: By the end of 2025, the company reported approximately $200 million in cash and investments with no debt, alongside an operating cash flow of $52 million for the year, demonstrating robust financial management and operational efficiency.
See More
